Lupin has launched Liraglutide injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen, in the United States (US).

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen is bioequivalent to Victoza injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and paediatric patients aged 10 years and older, with type-II diabetes mellitus.

As per IQVIA MAT Aug 2025, Liraglutide injection, 18 mg/3 mL (6 mg/mL) single-patient-use pre-filled pen (RLD Victoza) had an estimated annual sale of USD 350 million in the US.

Spiro Gavaris, President–US Generics, Lupin, said, “We are pleased to launch Liraglutide injection in the US. This marks a significant milestone in enhancing our portfolio of complex injectables and highlights our continued commitment to making essential therapies more accessible for patients.”